【摘要】 目的 提高對自身免疫性肝病的認(rèn)識。 方法 報(bào)道一例自身免疫性肝炎/原發(fā)性膽汁性肝硬化重疊綜合征誤診為藥物性肝炎,并綜述相關(guān)文獻(xiàn)總結(jié)其臨床表現(xiàn)、診斷、治療及預(yù)后。 結(jié)果 自身免疫性肝病是一組以肝臟病理損害和肝功能異常為主要表現(xiàn)的自身免疫性疾病,可分為自身免疫性肝炎(autoinmmune hepatitis,AIH)和(primary biliary cirrhosis,PBC)及原發(fā)性硬化性膽管炎(primary sclerosing cholangitis,PSC)。由于無特異性的臨床表現(xiàn),容易漏診或誤診為藥物性肝炎,診斷主要依靠生化及免疫學(xué)檢查。AIH/PBC重疊綜合征的治療目前無成熟經(jīng)驗(yàn),主要藥物包括熊去氧膽酸(UDCA)、糖皮質(zhì)激素和免疫抑制劑等。 結(jié)論 對于不明原因的肝損害患者應(yīng)做免疫學(xué)篩查。
引用本文: 王娟,唐紅. 自身免疫性肝炎/原發(fā)性膽汁性肝硬化重疊綜合征誤診為藥物性肝炎一例. 華西醫(yī)學(xué), 2010, 25(11): 2062-2063. doi: 復(fù)制
版權(quán)信息: ?四川大學(xué)華西醫(yī)院華西期刊社《華西醫(yī)學(xué)》版權(quán)所有,未經(jīng)授權(quán)不得轉(zhuǎn)載、改編
1. | Gheorghe L, Iacob S, Gheorghe C, et al. Frequency and predictive factors for overlap syndrome between aunoimmune hepatitis and primary cholestatic liver disease[J]. Eur J Gastroenterol Hepatol, 2004, 16(6): 585-592. |
2. | 姚光弼, 范上達(dá), 廖光杰. 臨床肝臟病學(xué)[M]. 上海: 上??茖W(xué)技術(shù)出版社, 2004: 437-454, 483-497. |
3. | 賈繼東. 自身免疫性肝病的基本概念和診斷思路[J]. 中華肝臟病雜志, 2005, 13(1): 54. |
4. | 溫小鳳, 蔣忠勝. AIH-PBC重疊綜合征的診斷及治療[J]. Chinese Hepatology. 2009, 14(5): 426-427. |
5. | Chazouillères O, Wendum D, Senfaty L, et al. Long tem outcome and response to therapy of primary biliary cirrhosis overlap syndrome[J]. J Hepatol, 2006, 44(2): 400-406. |
6. | ltakura J, Izumi N, Nishimura Y, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis[J]. Hepatol Res, 2004, 29(4): 216-212. |
- 1. Gheorghe L, Iacob S, Gheorghe C, et al. Frequency and predictive factors for overlap syndrome between aunoimmune hepatitis and primary cholestatic liver disease[J]. Eur J Gastroenterol Hepatol, 2004, 16(6): 585-592.
- 2. 姚光弼, 范上達(dá), 廖光杰. 臨床肝臟病學(xué)[M]. 上海: 上??茖W(xué)技術(shù)出版社, 2004: 437-454, 483-497.
- 3. 賈繼東. 自身免疫性肝病的基本概念和診斷思路[J]. 中華肝臟病雜志, 2005, 13(1): 54.
- 4. 溫小鳳, 蔣忠勝. AIH-PBC重疊綜合征的診斷及治療[J]. Chinese Hepatology. 2009, 14(5): 426-427.
- 5. Chazouillères O, Wendum D, Senfaty L, et al. Long tem outcome and response to therapy of primary biliary cirrhosis overlap syndrome[J]. J Hepatol, 2006, 44(2): 400-406.
- 6. ltakura J, Izumi N, Nishimura Y, et al. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis[J]. Hepatol Res, 2004, 29(4): 216-212.